Gerard Vockley
Expertise in
3
conditions

Dr. Gerard Vockley

Pediatrics
UPMC
Medical Genetics Metabolic In Lawrenceville
4401 Penn Avenue, 
Pittsburgh, PA 
On Staff At
Offers Telehealth

Expertise in
3
conditions
UPMC
Medical Genetics Metabolic In Lawrenceville
4401 Penn Avenue, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gerard (Jerry) Vockley MD, PhD, is a medical geneticist and is certified in clinical genetics and biochemical and molecular genetics by the American Board of Medical Genetics and Genomics. He is chief of the Division of Medical Genetics, director of the Center for Rare Disease Therapy, and is the Cleveland Family Endowed Professor of pediatric research at the University of Pittsburgh School of Medicine. He completed his medical degree and PhD at the University of Pennsylvania and completed his residency at the University of Colorado, followed by his fellowship at Yale University School of Medicine.

Dr. Vockley is highly rated in 3 conditions, according to our data. His top areas of expertise are Urea Cycle Disorders (UCD), Phenylketonuria (PKU), Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency, and Fabry Disease.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Pennsylvania Health System
Residency
University of Colorado Health Sciences Center
Specialties
Pediatrics
Licenses
Medical Genetics, Ph.D. Medical Genetics in PA
Board Certifications
American Board Of Medical Genetics And Genomics
American Board Of Medical Genetics And Genomics
Fellowships
Yale University School Of Medicine
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 13 Less Insurance Carriers -

Locations

Medical Genetics Metabolic in Lawrenceville
4401 Penn Avenue, Pittsburgh, PA 15224
Call: 412-692-5070

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


19 Clinical Trials

Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)
Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Phase: Phase 2
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: RAVICTI, NaPBA
Study Phase: Phase 4
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: REN001
Study Phase: Phase 2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
Hepatocyte Transplantation for Phenylketonuria
Hepatocyte Transplantation for Phenylketonuria
Enrollment Status: Terminated
Publish Date: August 16, 2023
Intervention Type: Drug, Other, Procedure, Diagnostic test, Radiation, Behavioral
Study Drug: Immunosuppression
Study Phase: Phase 1/Phase 2
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
Enrollment Status: Terminated
Publish Date: January 25, 2022
Intervention Type: Drug
Study Drug: KB195
Study Phase: Phase 2
A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics
A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics
Enrollment Status: Completed
Publish Date: May 13, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation
Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation
Enrollment Status: Terminated
Publish Date: May 23, 2019
Intervention Type: Dietary supplement
Study Phase: Not Applicable
Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome
Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome
Enrollment Status: No_longer_available
Publish Date: February 08, 2019
Intervention Type: Drug
View 18 Less Clinical Trials

4 Total Publications

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Journal: Journal of medical genetics
Published: July 19, 2016
View All 4 Publications
Similar Doctors
Expertise in
7
conditions
Dr. Uta Lichter-Konecki
Pediatrics | Medical Genetics
Expertise in
7
conditions
Dr. Uta Lichter-Konecki
Pediatrics | Medical Genetics

University Of Pittsburgh Physicians

4401 Penn Ave, 
Pittsburgh, PA 
 (0.1 miles away)
412-692-5520
Languages Spoken:
English
See accepted insurances

Uta Lichter-Konecki is a Pediatrics specialist and a Medical Genetics provider in Pittsburgh, Pennsylvania. Dr. Lichter-Konecki is highly rated in 7 conditions, according to our data. Her top areas of expertise are Urea Cycle Disorders (UCD), Phenylketonuria (PKU), Maple Syrup Urine Disease, and Hypotonia.

Alejandro M. Hoberman
Expertise in
3
conditions
Dr. Alejandro M. Hoberman
Pediatrics
Expertise in
3
conditions
Dr. Alejandro M. Hoberman
Pediatrics

Pediatric Primary Care (Upper Level) In Oakland

3420 5th Avenue, Upper Level, 
Pittsburgh, PA 
 (1.6 miles away)
412-692-6000
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Alejandro Hoberman graduated from medical school and general pediatrics residency in Buenos Aires, Argentina. He completed a General Academic Pediatrics fellowship at UPMC Children’s Hospital of Pittsburgh and joined the faculty at the University of Pittsburgh. He currently heads the Division of General Academic Pediatrics, is the executive vice chair and vice chair for Clinical Research in the Department of Pediatrics, and has been established as the Jack L. Paradise Distinguished Service Professor in honor of his research mentor. Dr. Hoberman also has administrative responsibilities as the president of UPMC Children’s Community Pediatrics, the largest primary care pediatrics organization in western and central Pa. with 58 offices including Express Care locations and over 1M yearly visits. Dr. Hoberman is very involved in research related to acute otitis media (AOM). He has contributed studies to enhance prevention, diagnosis, and treatment of this frequently occurring condition. He has also contributed studies related to prevalence, diagnosis, treatment, and follow-up imaging of urinary tract infections (UTI) in children. Click here to view Dr. Hoberman’s Department of Pediatrics bio page which has more information about his specific research endeavors, including publications, leadership positions, awards, and more. Click here to view Dr. Hoberman’s full list of publications from PubMed. Dr. Hoberman is highly rated in 3 conditions, according to our data. His top areas of expertise are Urinary Tract Infection in Children, Otitis Media with Effusion, High Blood Pressure in Infants, Diarrhea, and Myringotomy.

Expertise in
12
conditions
Dr. Benjamin L. Shneider
Pediatric Gastroenterology | Pediatrics
Expertise in
12
conditions
Dr. Benjamin L. Shneider
Pediatric Gastroenterology | Pediatrics
3705 5th Ave, Pediatric Gastroenterology, 
Pittsburgh, PA 
 (1.8 miles away)
412-692-5180
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Shneider is a Pediatric Gastroenterologist and a Pediatrics provider in Pittsburgh, Pennsylvania. Dr. Shneider is highly rated in 12 conditions, according to our data. His top areas of expertise are Biliary Atresia, Alagille Syndrome, Cholestasis, Liver Transplant, and Endoscopy. Dr. Shneider is currently accepting new patients.

VIEW MORE Pediatricians

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vockley's expertise for a condition
ConditionClose
      • Advanced
      • Phenylketonuria (PKU)
        Dr. Vockley is
        Advanced
        . Learn about Phenylketonuria (PKU).
        See more Phenylketonuria (PKU) experts
      • Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency
        Dr. Vockley is
        Advanced
        . Learn about Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency.
        See more Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency experts
      • Urea Cycle Disorders (UCD)
        Dr. Vockley is
        Advanced
        . Learn about Urea Cycle Disorders (UCD).
        See more Urea Cycle Disorders (UCD) experts
      • Experienced
      • Fabry Disease
        Dr. Vockley is
        Experienced
        . Learn about Fabry Disease.
        See more Fabry Disease experts
      • Mitochondrial Trifunctional Protein Deficiency
        Dr. Vockley is
        Experienced
        . Learn about Mitochondrial Trifunctional Protein Deficiency.
        See more Mitochondrial Trifunctional Protein Deficiency experts
      • Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
        Dr. Vockley is
        Experienced
        . Learn about Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency.
        See more Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency experts
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      1. Homepage
      2. Pediatricians Pittsburgh, PA
      3. Dr. Gerard Vockley
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.